Otsuka Pharmaceutical (TYO:4578) and Lundbeck said last week that its extended-release injectable aripiprazole suspension, Abilify Maintena, won FDA approval as a maintenance monotherapy for adults with bipolar I disorder.
The once-monthly intramuscular formulation was created by Otsuka and co-developed and commercialized with Lundbeck, the companies reported.
Get the full story at our sister site, Drug Delivery Business News.
The post Injectable, extended-release bipolar drug wins FDA nod appeared first on MassDevice.